Lunai Bioworks (LNAI) vs. The Competition Head to Head Survey

Lunai Bioworks (NASDAQ:LNAI) is one of 453 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Lunai Bioworks to similar businesses based on the strength of its analyst recommendations, valuation, earnings, risk, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Lunai Bioworks and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1	0	0	0	1.00
Lunai Bioworks Competitors	4820	9973	16010	372	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 111.84%. Given Lunai Bioworks’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Lunai Bioworks has less favorable growth aspects than its rivals.

Profitability

This table compares Lunai Bioworks and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-378.07%	-210.59%
Lunai Bioworks Competitors	-2,625.49%	-359.57%	-43.35%

Volatility and Risk

Lunai Bioworks has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Lunai Bioworks’ rivals have a beta of 10.21, indicating that their average share price is 921% more volatile than the S&P 500.

Earnings & Valuation

This table compares Lunai Bioworks and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lunai Bioworks	N/A	-$178.01 million	-15.43
Lunai Bioworks Competitors	$437.46 million	-$68.67 million	-10.42

Lunai Bioworks’ rivals have higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Lunai Bioworks rivals beat Lunai Bioworks on 11 of the 13 factors compared.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.